TAE Life Sciences
↗Irvine, California, United States
TAE Life Sciences is a privately-held biotechnology company focused on developing boron neutron capture therapy (BNCT) for treating refractory and difficult-to-treat cancers. Founded in 2017 as a subsidiary of TAE Technologies, the company is revolutionizing cancer treatment through proprietary BNCT technology that combines biologically-targeted boron drugs with accelerator-based neutron beam systems. The company's flagship Alphabeam™ BNCT system is designed as a compact, hospital-installable platform that delivers cancer-killing radiation with cellular-level precision, minimizing damage to healthy tissue. TAE Life Sciences is the only company developing next-generation targeted boron drugs (BTS) alongside a low-energy accelerator-based neutron system optimized for in-hospital BNCT programs to treat patients with aggressive and refractory cancers including head and neck, glioblastoma, melanoma, and other difficult-to-treat malignancies.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2017
Ownership:private
Status:operating
FUNDING
Stage:Series B
Total Raised:$70M
Investors:ARTIS Ventures, Big Sky Partners, Neuboron Medical, Rising Tide Fund
PIPELINE
Stage:Investigator Initiated Trials (IIT) - Early clinical stage
Lead Drug Stage:Investigator Initiated Trials
Modalities:Boron Neutron Capture Therapy (BNCT), Accelerator-based neutron beam therapy
Active Trials:1
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:TAE Technologies (fusion energy company)
Key Partnerships:Stella Pharma: Strategic collaboration on BPA (boronophenylalanine) development and commercialization for BNCT in USA and Europe; TLS serves as exclusive commercial partner for Stella's BPA in these regions; clinical trials anticipated to begin 2026, Neuboron Medical: Partnership for BNCT development and commercialization; Neuboron operates first accelerator-based BNCT clinical center at Xiamen Humanity Hospital in China; system has treated 22 patients, University of Wisconsin-Madison: MOU to establish first US accelerator-based BNCT center; planned as first US clinical trial site for head and neck and brain cancers; installation scheduled 2025, trials to launch, CNAO (Italian National Center for Oncological Hadrontherapy): Definitive agreement for BNCT collaboration; Alphabeam system installation scheduled to begin 2025, clinical trials launching 2026, alphaXRT: Distribution agreement for Alphabeam BNCT system and boron drugs in Australia and New Zealand (April 2025), Radiosurgery Global: Distribution deal announced June 2024
COMPETITION
Position:Leader
Competitors:Sumitomo Heavy Industries, Neutron Therapeutics International, Particle Therapy Inc (IPT), RaySearch Laboratories, Neuboron Medtech (China), Stella Pharma (drug partner/competitor), 21st Century Oncology, Accuray +1 more
LEADERSHIP
Key Executives:
Rob Hill - Chief Executive Officer
Anna Theriault - General Manager, Americas & Global VP of Marketing
Bruce Bauer - Chairman Emeritus
Scientific Founders:Norman Rostoker (TAE Technologies co-founder; deceased 2014)
Board Members:Bruce Bauer (Chairman Emeritus), Rob Hill (CEO), Board includes members shared with parent company TAE Technologies
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with TAE Life Sciences. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.